---
title: "DENALI CAPITAL ACQUISITION CORP UNIT 1 ORD A & 1 WT EXP (28/03/2027) | 10-Q: FY2025 Q2 EPS: USD -0.15"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253211103.md"
datetime: "2025-08-15T11:51:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253211103.md)
  - [en](https://longbridge.com/en/news/253211103.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253211103.md)
generator: "portal-rs"
---

# DENALI CAPITAL ACQUISITION CORP UNIT 1 ORD A & 1 WT EXP (28/03/2027) | 10-Q: FY2025 Q2 EPS: USD -0.15

EPS: As of FY2025 Q2, the actual value is USD -0.15.

### Segment Revenue

-   The company has not commenced any operations and does not expect to generate operating revenues until after the completion of an initial Business Combination.

### Operational Metrics

-   **Net Loss**: For the three months ended June 30, 2025, the company reported a net loss of $385,122, compared to a net income of $448,912 for the same period in 2024.
-   **Formation and Operating Costs**: For the three months ended June 30, 2025, formation and operating costs were $374,857, compared to $168,186 for the same period in 2024.
-   **Interest Expense**: For the three months ended June 30, 2025, interest expense was $28,345, compared to $23,059 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: For the six months ended June 30, 2025, net cash used in operating activities was $183,512.
-   **Net Cash Provided by Investing Activities**: For the six months ended June 30, 2025, net cash provided by investing activities was $8,617,553, primarily due to cash withdrawn from the trust account in connection with redemption.
-   **Net Cash Used in Financing Activities**: For the six months ended June 30, 2025, net cash used in financing activities was $8,450,783, primarily due to cash paid for redemption of ordinary shares.

### Unique Metrics

-   **Trust Account**: As of June 30, 2025, the company had $548,318 held in the Trust Account, which is intended to be used to complete the Business Combination.

### Future Outlook and Strategy

-   **Core Business Focus**: The company is focused on completing its initial business combination, with a proposed merger agreement with Semnur Pharmaceuticals, Inc. The total consideration to be paid at closing will be $2,500,000,000, payable in New Semnur Common Shares.
-   **Non-Core Business**: The company has entered into various agreements, including a Sponsor Interest Purchase Agreement and a Stockholder Agreement, to facilitate the business combination with Semnur Pharmaceuticals, Inc.
-   **Priority**: The company has extended its combination period through December 11, 2025, and is actively working towards completing the business combination with Semnur Pharmaceuticals, Inc.

### Related Stocks

- [DNQUF.US](https://longbridge.com/en/quote/DNQUF.US.md)

## Related News & Research

- [Bitget rebuilt a $309 million protection fund after a $388 million hack. Is your crypto safe on an exchange?](https://longbridge.com/en/news/300866532.md)
- [Average analyst price target for Accsys Technologies increased by 11.37% to €0.01](https://longbridge.com/en/news/300865749.md)
- [Goldpesa Suffers About $114,900 Loss in Attack Linked to GPXHooks Rebalance Flaw](https://longbridge.com/en/news/300869009.md)
- [SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026](https://longbridge.com/en/news/300869024.md)
- [Midnight: Midnight City plans to enable AI agent trading - Q4 2026](https://longbridge.com/en/news/300868349.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**